EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Severe Cutaneous Adverse Reactions Associated With Newer‐Generation Antiseizure Medications: A Real‐World Pharmacovigilance Study Based on FAERS and JADER

Longfei You, Dong Zhang, Zhihua Cheng, Yinbao Qi, Ruobing Qian iD

CNS Neuroscience & Therapeutics · 2026-06 · 32 (6)

DOI: 10.1002/cns.70972 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 05.06.2026. Verfasst von Longfei You und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Anticonvulsants, Pharmacovigilance, Drug Eruptions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Medical Artificial Intelligence Joint Fund, the China Association Against Epilepsy (CAAE) Epilepsy Research Fund, the Research Fund Project of Anhui Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Severe cutaneous adverse reactions (SCARs) are rare but potentially fatal immune‐mediated toxicities associated with antiseizure medications (ASMs). Phenotype‐resolved post‐marketing safety profiles for newer‐generation ASMs have not been comprehensively characterized across pharmacovigilance systems.

Methods

A cross‐database disproportionality analysis was conducted using FAERS and JADER (January 2004–September 2025). Twenty‐two newer‐generation ASMs coded as primary‐suspect drugs were included; outcomes were the four SCAR phenotypes (Stevens–Johnson syndrome, SJS; toxic epidermal necrolysis, TEN; drug reaction with eosinophilia and systemic symptoms, DRESS; acute generalized exanthematous pustulosis, AGEP) defined using MedDRA preferred terms. Signals were evaluated using reporting odds ratios (RORs) and Bayesian information component metrics. Time‐to‐onset (TTO) was characterized by Weibull modeling with confidence‐interval–based failure‐pattern classification and Kaplan–Meier analysis. Pre‐specified sensitivity analyses excluded reports with concomitant valproic acid or other SCAR‐inducing co‐medications, applied multivariate logistic regression, and restricted FAERS reports to healthcare professionals.

Results

In total, 10,073 SCAR reports were included (SJS, 3776; TEN, 1762; DRESS, 4298; AGEP, 237). Lamotrigine and zonisamide showed the strongest, most reproducible associations across SJS/TEN/DRESS (FAERS RORs for lamotrigine, 35.60/22.35/27.30; zonisamide, 28.08/25.05/40.78), with concordant directions in JADER. Sensitivity analyses attenuated but did not abolish the principal lamotrigine, zonisamide, levetiracetam, and eslicarbazepine signals, whereas the gabapentin–TEN signal in JADER lost statistical significance after exclusion of high‐risk co‐medications. Median TTO was 22 days overall; SJS/TEN occurred earlier, while DRESS showed delayed and more dispersed onset (median, 28 days), with eslicarbazepine–DRESS uniquely exhibiting a wear‐out pattern. TEN carried the highest reported fatality proportion (FAERS, 17.7%; JADER, 17.5%). Key signals remained robust under healthcare‐professional restriction, with eslicarbazepine–DRESS further enhanced.

Conclusions

Across FAERS and JADER, reporting associations between newer‐generation ASMs and SCARs were highly concentrated in a limited set of agents and exhibited phenotype‐specific latency patterns. After accounting for polytherapy confounding, levetiracetam and eslicarbazepine emerged as the most consistent under‐recognized signals, warranting heightened vigilance during initiation—particularly when co‐administered with aromatic ASMs. Drug–phenotype combinations with both high disproportionality and a high reported fatality proportion (notably lamotrigine–TEN and zonisamide–TEN) warrant intensified early monitoring for SJS/TEN and sustained vigilance into maintenance therapy for DRESS, although population‐level absolute risk cannot be inferred from spontaneous‐report data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsPharmacovigilanceDrug EruptionsHumansFemaleMaleAdverse Drug Reaction Reporting SystemsMiddle AgedAdultDatabases, FactualStevens-Johnson SyndromeYoung AdultAged

Stichwörter der Autor:innen

FAERSJADERdisproportionality signal detectionnewer‐generation antiseizure medicationspharmacovigilance databasessevere cutaneous adverse reactions

Substanzen

Anticonvulsants

Autor:innen und Institutionen

  • Department of Neurosurgery, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Department of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.

ORCID-Profile: Ruobing Qian

Förderung

  • the Medical Artificial Intelligence Joint Fund
  • the China Association Against Epilepsy (CAAE) Epilepsy Research Fund
  • the Research Fund Project of Anhui Medical University

Zitieren

APA

You, L., Zhang, D., Cheng, Z., Qi, Y., & Qian, R. (2026). Severe Cutaneous Adverse Reactions Associated With Newer‐Generation Antiseizure Medications: A Real‐World Pharmacovigilance Study Based on FAERS and JADER. CNS Neuroscience & Therapeutics, 32(6). https://doi.org/10.1002/cns.70972

Vancouver

You L, Zhang D, Cheng Z, Qi Y, Qian R. Severe Cutaneous Adverse Reactions Associated With Newer‐Generation Antiseizure Medications: A Real‐World Pharmacovigilance Study Based on FAERS and JADER. CNS Neuroscience & Therapeutics. 2026;32(6). doi:10.1002/cns.70972

BibTeX
@article{You2026,
  author = {You, Longfei and Zhang, Dong and Cheng, Zhihua and Qi, Yinbao and Qian, Ruobing},
  title = {Severe Cutaneous Adverse Reactions Associated With Newer‐Generation Antiseizure Medications: A Real‐World Pharmacovigilance Study Based on FAERS and JADER},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  volume = {32},
  number = {6},
  doi = {10.1002/cns.70972}
}
Kostenlos starten →